Analyst firms · UBS · GMAB
UBS GMAB price target and rating history
Genmab A/S (GMAB) · Health Care
UBS rates Genmab A/S (GMAB) Buy, as of its latest action on Dec 6, 2023. It has published 3 rating actions on GMAB since March 2022, including 2 upgrades and 0 downgrades. Across 6 firms with a GMAB price target in the last 12 months, the median target is $40.
- Current rating
- Buy
- Price target
- Not stated
- Median target, all firms
- $40
- Actions on GMAB
- 3
Every UBS rating on GMAB
- Dec 6, 2023
- May 31, 2023InitiateUBS starts coverage at Neutral
- Mar 16, 2022
How other firms rate GMAB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| TD Cowen | Buy | $43 | Jul 22, 2026 |
| Truist Securities | Buy | $40 | May 27, 2026 |
| Goldman Sachs | Buy | Apr 22, 2026 | |
| Wolfe Research | Outperform | $32 | Mar 27, 2026 |
| Wells Fargo | Overweight | $40 | Mar 2, 2026 |
| Jefferies | Buy | $41.50 | Feb 17, 2026 |
| Morgan Stanley | Equal-Weight | $34 | Feb 17, 2026 |
Questions about UBS and GMAB
- What is UBS's rating on GMAB?
- UBS rates GMAB Buy, a bullish rating, as of Dec 6, 2023.
- When did UBS last change its view on GMAB?
- On Dec 6, 2023, UBS upgrades to Buy from Neutral.
- How does UBS's GMAB target compare with other analysts?
- Across 6 firms with a GMAB price target in the last 12 months, the median target is $40.
More GMAB rating histories
All UBS ratingsGMAB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.